Physical functioning - Longitudinal Aging Study Amsterdam

In the table below, entries in the left column refer to the related documentation, while the values in the cells of columns LASA-B to LASA-J refer to the corresponding LASA-data files (e.g. ‘161‘ in column B refers to: ‘LASAB161‘). Table entries are hyperlinks. Hovering over the waves in the header will show the years in which the corresponding measurements took place.

In case entries are preceeded by ‘o’, the corresponding files are related to the OSTEOPOR-dataset (e.g. o80 refers to ‘LASAo80′). Likewise, prefixes ‘g’, ‘z’, ‘zo(a)’, ‘zh’, ‘ch’, and ‘zd’ refer to other special datasets, more information will follow.

UC: Under Construction.

For more details about the LASA-waves, see Design LASA.

Note that some of the data are not yet available (in red).

LASA-WAVE	B	C	D	E	2B	F	G	H	3B	MB	I	J	K
Cohort 1
Cohort 2
Cohort 3
Migrant Cohort

THEME PHYSICAL
Blood pressure	B	C	D	E	2B	F	G	H	3B	MB	I	J	K
Blood pressure/pulse – retests	151 –	151 –	151 –	151 –	151 151	151 –	151 151	151 151	151 151	151 –	151 151	151 151	151 151

Body composition	B	C	D	E	2B	F	G	H	3B	MB	I	J	K
Anthropometry – Weight and height – Calf measurement – Ankle, Knee and Pulse width	161 161 171 –	161 161 – 185	161 161 171 –	161 161 171 –	161 161 171 –	161 161 171 –	161 161 171 –	161 161 171 –	161 161 171 –	161 161 – –	161 161 161 –	161 161 161 –	161
Weight and height: history and weight change^IM – tel. respondent*	160 –	160 –	160 –	160 –	160 –	160 –	160 –	160 –	160 –	160 –	160 714	160 714	160 714
Bio-electrical impedance (BIA) (subsample)	172	–	–	–	–	–	–	–	–	–	–	–	–
Birth weight	–	–	–	134	134	–	–	–	134	–	–	–	–
Perceived body shape – scaled	– –	– –	– –	– –	– –	145 345	145 345	– –	145 345	145 –	– –	– –	– –
DXA (LASA ancillary study) – Hip / lumbar spine scan – Whole body scan	– –	o41 o42	o41 o42	– –	– –	– –	– –	– –	– –	– –	– –	– –	– –

Chronic diseases	B	C	D	E	2B	F	G	H	3B	MB	I	J	K
Self-report of chronic diseases^IM – nr. of diseases reported – tel. proxy* – tel. respondent* – longitudinally cleaned	035 235 – – 435	035 235 602 702 435	035 235 602 702 –	035 235 602 702 –	035 235 – – –	035 235 602 702 –	035 235 602 702 –	035 235 602 702 –	035 235 – – –	035 235 – – –	035 235 602 702 –	035 235 602 702 –	035 235 602 702 –
GP information	g01	g01	–	g01	g01	UC	–	g01	g01	–
Aortic calcification (lateral radiographs)	–	zo22	zo22	–	–	–	–	–	–	–	–	–	–
Diabetes mellitus (algorithm)	zdc1	zdc1	zdc1	zdc1	zdc2	zdc1 zdc2	zdc1 zdc2	zdc1 zdc2	zdc3	–	zdc1 zdc2 zdc3	UC	UC
Rheumatoid Arthritis (algorithm)	–	UC	–	–	–	–	–	–	–	–	–	–	–
Osteoarthritis hip and knee (algorithm)	zoa1	zoa1	zoa1	zoa1	zoa2	zoa1 zoa2	zoa1 zoa2	zoa1 zoa2	zoa3	–	zoa1 zoa2 zoa3	UC	UC
Metabolic syndrome	–	ch02	–	–	–	–	–	–	–	–	–	–	–
Allostatic Load (algorithm)	–	X	–	–	–	–	–	–	–	–	–	–	–
Intrinsic Capacity
Cardiovascular diseases (algorithm)	zh01	zh01	zh01	zh01	zh01	zh01	zh01	zh01	zh01	zh01	zh01	–	–
Parkinson: early P. related signs	–	–	–	–	–	–	–	–	096	096	–	–	–
Decubitus (bedsores)	116 159	– –	– –	– –	– –	– –	– –	– –	– –	– –	– –	– –	– –
Hyperthyroidism	–	182	182	–	–	–	–	–	–	–	–	–	–
Back pain	–	182	182	182	–	–	–	–	–	–	–	–	–
Bedridden	–	182	182	–	–	182	182	182	182	–	–	–	–

Fertility	B	C	D	E	2B	F	G	H	3B	MB	I	J	K
Fertility (women)	119	181¹	–	–	181	–	–	–	181	181	–	–	–

Falling	B	C	D	E	2B	F	G	H	3B	MB	I	J	K
Falls – tel. proxy* – tel. respondent* – Falls last year	– – –	605 705 187	605 705 187	– – –	– – –	– – –	– – –	– – –	– – 187	– – 187	– – –	– – 187	– – 187
Falls: circumstances and consequences	–	–	187	–	–	–	–	–	–	–	–	187	187
Falls: environmental conditions (home)**	–	180	180	–	–	–	–	–	–	–	–	–	–
Falls: fear of falling (FES: Falls Efficacy Scale)	–	183	183	–	–	–	–	–	–	–	–	–	–
Falls: prevention of fall accidents (LASA ancillary study)	–	–	X	–	–	–	–	–	–	–	–	–	–
Falls: 3y prospective fall calendar (LASA ancillary study)	–	X	–	–	–	–	–	–	–	–	–	–	–
Falls: 1y prospective fall calendar (LASA ancillary study)	–	–	–	–	–	–	X	–	–	–	–	–	–
Dizziness^IM	–	187	187	–	187	187	187	187	187	–	187	187	187
Walking aids	–	–	187	187	187	187	187	187	187	–	–	–	–
Foot problems	–	185	185	185	–	185	–	–	–	–	–	–	–

Fractures	B	C	D	E	2B	F	G	H	3B	MB	I	J	K
Fractures – total waves B-F – per wave – tel. proxy* – tel. respondent*	zo13 – – –	zo13 186 605 705	zo13 186 605 705	zo13 186 605 705	zo13 186 – –	zo13 186 605 705	186 605 705	186 605 705	186 – –	186 – –	186 605 705	186 605 705	186 605 705
Vertebral deformities	–	zo22	zo22	–	–	–	–	–	–	–	–	–	–
Quantitative ultrasound of bone	–	o31	–	–	–	–	o31	–	–	–	–	–	–

Frailty	B	C	D	E	2B	F	G	H	3B	MB	I	J	K
Various definitions (e.g., frailty phenotype, frailty index)	X	X	X	X	X	X	X	X	X	X	X	X

Lifestyle	B	C	D	E	2B	F	G	H	3B	MB	I	J	K
Alcohol use^IM – scaled	153 353	153 353	153 353	153 353	153 353	153 353	153 353	153 353	153 353	153 353	153 353	153 353	153 353
Coffee and tea consumption	–	–	–	–	–	–	–	–	–	–	–	801	801
Diet and food consumption Lifestyle study (LASA ancillary study) Nutrition and food-related behaviour (LASA ancillary study) with subtopics: – Eating patterns – Weight(loss) and appetite – Mindful eating – Meals and snack – Interoceptive awareness of hunger and satiety – Alexithymia – Binge eating – Eating styles – Problems food intake – Use of amenities – Food products for older adults – Dietary recommendations – Sustainable behaviour – Change in sleep and appetite	118 – –	118 184 –	118 184 –	– – –	– – –	– – X	– – –	118 – –	– – –	– – –	118 – –	118 – –	118 – –
MicMac study (LASA ancillary study)											X
Oral health	–	–	–	–	–	X²	–	–	–	–	126	126	126
Physical activity ^IM	046	046	046	046	046	046	046	046	046	046	046	046	046
Daily Physical Activity	–	–	–	–	–	–	–	–	–	–	–	162	–
Early life physical activity	–	246	–	–	–	–	–	–	–	–	–	–	–
Perceived physical activity (LIVAS) – scaled	114 314	114 314	114 314	114 314	114 314	114 314	– –	– –	– –	– –	– –	– –	– –
Accelerometry (LASA ancillary studies) – subsample (St. 1) – subsample (St. 2) – subsample (St. 3) – subsample (St. 4)	– – – –	– – – –	– – – –	– – – –	– – – –	X² – – –	– X – –	– – X³ –	– – – –	– – – –	– – – X	– – – –	– – – –
Sedentary behavior – scaled – scaled	– – –	– – –	– – –	– – –	– – –	– – –	101 301 501	101 301 501	101 301 501	101 301 501	101 301 501	101 301 501	101 301 501
Smoking^IM	154	154	154	154	154	154	154	154	154	154	154	154	154

Medication/ supplements	B	C	D	E	2B	F	G	H	3B	MB	I	J	K
Medication and food supplement use⁴ – types of medication	152 352	152 352	152 352	152 352	152 352	152 352	152 352	152 352	152 352	152 352	152 352	152 352	152 352
Food supplement use⁴ – Vitamin D use included	– –	– –	– –	– –	– –	– –	– –	– –	– –	– –	174 374	174 374	174 374

Pain	B	C	D	E	2B	F	G	H	3B	MB	I	J	K
Subjective pain^IM – scaled	115 315	115 315	115 315	115 315	115 315	115 315	115 315	115 315	115 315	115 315	115 315	115 315	115 315
Dealing with pain**	–	–	–	188	–	–	–	–	–	–	–	–	–
Pain drawing	–	–	–	188	–	–	–	–	–	–	–	–	–

Perception: Vision	B	C	D	E	2B	F	G	H	3B	MB	I	J	K
Vision (self-report)^IM – total scores – tel. proxy* – tel. respondent*	031 231 – –	031 231 604 704	031 231 604 704	031 231 604 704	031 231 – –	031 231 604 704	031 231 604 704	031 231 604 704	031 231 – –	031 – – –	031 231 604 704	031 231 604 704	031 231 604 704
Visual acuity test – Vision-related quality of life	– –	– –	– –	191 192	– –	191 192	191 192	191 192	191 –	– –	– –	– –	– –
Vision: contrast sensitivity	157	157	157	157	157	157	–	–	–	–	–	–	–

Perception: Hearing	B	C	D	E	2B	F	G	H	3B	MB	I	J	K
Hearing (self-report)^IM – total scores – tel. proxy* – tel. respondent*	031 231 – –	031 231 604 704	031 231 604 704	031 231 604 704	031 231 – –	031 231 604 704	031 231 604 704	031 231 604 704	031 231 – –	031 – – –	031 231 604 704	031 231 604 704	031 231 604 704
Hearing: Speech in Noise Test (SNT) Hearing: SNT questions	– –	– –	– –	193 194	– –	193 194	193 194	– –	– –	– –	193 194	– –	– –

Perception: smell	B	C	D	E	2B	F	G	H	3B	MB	I	J	K
Olfactory function	–	–	–	–	–	–	–	–	S00 S01 S02	S00 S01 S02	–	–	–

Physical functioning	B	C	D	E	2B	F	G	H	3B	MB	I	J	K
Funct. limitations (ADL)^IM – constructed – tel. proxy* – tel. respondent* Use of assistive devices or assistance Limitations in joint mobility Funct. limitations partner (ADL)	030 230 – – 030 – –	030 230 603 703 030 183	030 230 603 703 030 183 –	030 230 603 703 030 183 139	030 230 – – 030 – –	030 230 603 703 030 – 139	030 230 603 703 030 – 139	030 230 603 703 030 – 139	030 230 – – 030 – 139	030 230 – – 030 – –	030 230 603 703 030 – 139	030 230 603 703 030 – 139	030 230 603 703 030 – 139
Global Activity Limitations – tel. respondent*	033 –	033 703	033 703	033 703	033 –	033 703	033 703	033 703	033 –	– –	033 703	033 703	033 703
Physical performance	034	034	034	034	034	034	034	034	034	034	034	034	034
Pulmonary function test – Peak Flow – Spirometry (post bronchodilator)	158 –	158 –	158 –	158 –	–	– –	158 –	158 –	– 168	– –	– –	– –	– –
Grip strength	–	161	161	161	161	161	161	161	161	161	161	161	161

Quality of life	B	C	D	E	2B	F	G	H	3B	MB	I	J	K
EuroQol – scaled	– –	– –	– –	135 335	– –	135 335	135 335	135 335	135 335	– –	135 335	– –	– –
Qualeffo-41 – (non)response – Qualeffo scores – total scores	– – –	– – –	– – –	o80 o81 o82	– – –	– – –	– – –	– – –	– – –	– – –	– – –	– – –	– – –
SF-12 Health Survey – scaled – scaled (Am.)	– – –	– – –	133 333 533	133 333 533	– – –	133 333 533	133 333 533	133 333 533	133 333 533	– – –	133 333 533	133 333 533	133 333 533
WHO Quality of Life**	–	–	–	–	–	–	–	–	–	–	133	133	133
Self-rated health – GHPQ – GHPQ: scaled – tel. proxy* – tel. respondent*	036 113 313 – –	036 113 313 602 702	036 113 313 602 702	036 113 313 602 702	036 113 313 – –	036 113 313 602 702	036 113 313 602 702	036 113 313 602 702	036 113 313 – –	036 – – – –	036 – – 602 702	036 – – 602 702	036 – – 602 702
#

LASA-wave	B	C	D	E	2B	F	G	H	3B	MB	I	J	K

* Files in the 700 series contain data from telephone interviews held with respondents, while files in the 600 series contain data from telephone interviews held with proxies.

** Not yet documented

¹ Fertility (Women) moved from self-administered questionnaire (LASAB119) to medical interview (LASAC181 / LAS2B181 / LAS3B181 / LASMB181)

² As part of the Lifestyle study

³ As part of the EPOSA study

⁴ In wave I Food supplement questions moved to LASA174

^IM In 2004, three years after wave E an interim measurement was carried out on the first cohort, see the specific topics for more details. More information will follow.